IPF Patients and Doctors Looking for New Treatment Options

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_ipf doctors

Spherix Global Insights, GmbH, a business intelligence and market research company based in Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms of treatment, especially sinceĀ the majority of patients are diagnosed at already advanced disease stages. The Spherix study is entitled ā€œMarket Dynamix: Idiopathic Pulmonary Fibrosis (IPF).ā€

Currently, there are two approved drugs for IPF treatment: Esbriet (pirfenidone), developed by Roche, and Ofev (nintedanib), developed by Boehringer Ingelheim. Several companies are exploring potential new therapies, including MediciNova (tipelukast), Biogen (STX-100), Gilead (simtuzumab), Afferent (AF-219), and FibroGen (FG-3019). However, according to a Spherix press release, physicians are not well-informed concerning future therapeutic options for IPF and the potential benefits they may offer.

Read more about it:Ā http://bit.ly/22MCruQ